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Abstract: If chronic kidney disease (CKD) is associated with an impairment of kidney function,
several uremic solutes are retained. Some of these exert toxic effects, which are called uremic toxins.
p-Cresyl sulfate (pCS) is a prototype protein-bound uremic toxin to which many biological and
biochemical (toxic) effects have been attributed. In addition, increased levels of pCS have been
associated with worsening outcomes in CKD patients. pCS finds its origin in the intestine where gut
bacteria metabolize aromatic amino acids, such as tyrosine and phenylalanine, leading to phenolic end
products, of which pCS is one of the components. In this review we summarize the biological effects of
pCS and its metabolic origin in the intestine. It appears that, according to in vitro studies, the intestinal
bacteria generating phenolic compounds mainly belong to the families Bacteroidaceae, Bifidobacteriaceae,
Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Eubacteriaceae, Fusobacteriaceae, Lachnospiraceae,
Lactobacillaceae, Porphyromonadaceae, Staphylococcaceae, Ruminococcaceae, and Veillonellaceae. Since pCS
remains difficult to remove by dialysis, the gut microbiota could be a future target to decrease pCS
levels and its toxicity, even at earlier stages of CKD, aiming at slowing down the progression of the
disease and decreasing the cardiovascular burden.
Keywords: p-cresyl sulfate; intestinal microbiota; chronic kidney disease
1. Introduction
When kidney function deteriorates, a myriad of compounds, the so-called uremic retention solutes,
accumulate in the circulation and tissues [1–3]. As a consequence, progression of kidney dysfunction
is paralleled with the development of complications, affecting both the quality of life and survival
of patients with chronic kidney disease (CKD) [4–7]. Uremic retention solutes are, conventionally,
classified into three groups based on their physicochemical characteristics [2]. Next to the small
water-soluble compounds (<500 Da) and the larger middle molecules (mostly peptidic compounds
with molecular weight >500 Da) the protein-bound compounds form a third group. Many of
these compounds, amongst which the phenols and indoles, originate from the intestinal microbial
metabolism of dietary amino acids [8]. Whereas in the healthy kidney, removal of protein-bound
solutes largely depends on tubular secretion, removal by dialysis, primarily replacing the filtration
capacity of the kidney, is limited to the unbound fraction and is not affected by dialyzer pore size [9],
and only marginally by convection [10]. Hence, dialysis removal is unsatisfactory, compared to,
e.g., the low molecular weight compounds which are not bound to protein. For the protein-bound
compounds alternative measures, preferably preventive (such as decreasing generation, adsorption,
and preserving kidney function), will be necessary to keep concentrations low. In this review, p-cresyl
sulfate (pCS), a prototype protein-bound molecule, to which many biological and biochemical (toxic)
actions have been attributed, and for which increased concentrations have been associated with
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worsening outcomes (see below), will be discussed in depth. We will especially focus on the intestinal
origin of pCS and the contributing bacterial species which could be a future target to decrease levels
and hence toxicity, even at earlier stages of CKD, aiming at slowing down the progression of the
disease and decreasing the cardiovascular burden.
2. Characteristics of p-Cresyl Sulfate
2.1. Chemical Structure and Molecular Weight
The aromatic pCS originates from sulfation (para-) of the intestinally generated p-cresol
(MW: 108.1 g/mol). pCS (C7H8O4S) (Figure 1) has a molecular weight of 188.2 g/mol and in the
circulation (plasma) it is bound for approximately 95% to the protein albumin in healthy controls, as
well as in CKD patients [11].
2.2. Normal and Uremic Serum/Plasma Concentrations
Normal total average serum/plasma concentrations of pCS reported, vary between 2.8 ± 1.7 mg/L
(14.9± 9.0µM) [12] and 6.6± 3.7 mg/L (35.1± 19.7µM) [13] as determined in serum by ultra-performance
liquid chromatography (UPLC) and UPLC-mass spectrometry (MS)-MS, respectively. In end-stage kidney
disease (ESKD), concentrations of pCS are significantly increased with total average concentrations
varying from 21.8 ± 12.4 mg/L (115.8 ± 65.9 µM) [14] to 106.9 ± 44.6 mg/L (568.0 ± 237.0 µM) [15], as
quantified by UPLC in serum and LC-MS-MS in plasma, respectively.
3. Metabolism
3.1. p-Cresyl Sulfate, a Colon-Derived Solute
The gut microbiota plays an important role in human health and disease [16,17], with alterations
of the intestinal microbiota linked to the development of different diseases, such as inflammatory
bowel disease [18], cancer [19], obesity [20], diabetes [21,22], cardiovascular disease [23], and
kidney disease [24]. Next to protection against invading pathogens and differentiation of the human
immune system, the microbiota contributes to various metabolic functions, such as fermentation
of non-digestible dietary compounds in the large intestine [17,25,26]. Approximately 6–18 g of
proteins and peptides enters the large intestine every day, mostly from diet, and to a lesser extent
from endogenous sources, such as host tissues, pancreatic enzymes, and other secretions [27–29].
Entering the large bowel, these substances undergo depolymerization by host- and bacteria-derived
proteases and peptidases into small oligopeptides and amino acids. These small oligopeptides and
amino acids are then available for assimilation by colon microbiota or can be further metabolized by
host enzymes [30,31]. Predominantly in the distal part of the colon, the aromatic amino acids tyrosine
and phenylalanine are converted into phenolic compounds, such as phenol and p-cresol, through a
series of deamination, transamination, and decarboxylation reactions by bacterial fermentation [29,32]
(Figure 1). Detoxification of phenols occurs in the mucosa of the colon [33] and in the liver [34],
where, e.g., p-cresol is sulfated into pCS and a small fraction is glucuronated into p-cresyl glucuronide
(pCG) [35,36]. When entering the circulation these solutes bind to plasma albumin in a reversible
manner, such that a rapid equilibrium between the bound and free fraction is established [37]. Finally,
under normal conditions, the free fraction of these compounds is filtered at the site of the glomerulus
and the bound fraction is secreted at the site of the tubular epithelial cells and both end up in the urine.
In CKD patients, excretion of these solutes is impaired, resulting in their accumulation. Of note, in
CKD estimates of proximal tubular secretion function and glomerular filtration of pCS correlate to
each other to a certain extent, but that substantial variability in the change of net secretion vs. normal
by the two components of the kidney remains [38]. In many studies plasma/serum and urine levels of
p-cresol are reported. It is of note that these levels reflect the sum of both conjugates, pCS and pCG,
since p-cresol is not present at detectable levels in the circulation [39].
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Figure 1. Conversion pathway of tyrosine and phenylalanine into p-cresyl sulfate. Full arrows: process
through bacterial fermentation; dotted arrows: process through enzymatic reactions of the host; EC: enzyme
commission number. L-tyrosine, derived from diet and endogenous proteins and peptides, can be
converted to phenol and 4-hydroxyphenylpyruvate. Tyrosine phenol-lyase (EC 4.1.99.2.), previously
named β–tyrosinase, is responsible for the reversible deamination of L-tyrosine, requiring pyridoxyl
phosphate as a cofactor, into phenol ammonia and pyruvate [40–42]. This reaction is also reversible by
the same enzyme using L-serine and phenol as substrates [43]. In addition, the reversible reaction of
L-tyrosine with 2-oxoglutarate in 4-hydroxyphenylpyruvate and L-glutamate is catalysed by tyrosine
trans minase (EC 2.6.1.5.) or by aromatic-amino-acid transaminase (EC 2.6.1.57.) [44–46]. To a small extent,
4-hydr xyphenylpyruvate and a monia can also be formed by the enzyme phenylalanine dehydrogenase
(EC 1.4.1.20.) from L-tyrosine [47]. 4-Hydroxyphenylpyruvate is the precursor of 4-hydroxyphenylacetate,
catalyse by p- ydroxyphenylpyruvate oxidase (EC 1.2.3.13.) [44,46], and can subsequently lead to the
formation of p-cresol by p-hydroxyphenylacetate decarboxylase (EC 4.1.1.83.) [48,49]. In the gut mucosa
and in the liver, the majority of p-cresol will be conjugated into the uremic toxin p-cresyl sulfate by
aryl sulfotransferases (EC 2.8.2.1.) [50] and a small fraction will be metabolized to p-cresyl glucuronide
by UDP-glucuronyltransferases (EC 2.4.1.17.) [51]. Another aromatic amino acid, phenylalanine,
also plays a role in the production of p-cresyl sulfate through the hydroxylation reaction to tyrosine
by phenylalanine 4-monooxygenase, also referred as phenylalanine hydroxylase (EC 1.14.16.1.) [52].
This metabolic process is carried out by bacteria as well by liver cells, transforming excess diet
phenylalanine to tyrosine [53]. In addition, phenylalanine is converted into 3-phenylpyruvate by
either phenylalanine dehydrogenase (EC 1.4.1.20.) [47,54], branched-chain-amino-acid transaminase
(EC 2.6.1.42.) [55] or by aromatic-amino-acid transaminase (EC 2.6.1.57.) [45]. Then 3-phenylpyruvate
can be transformed in 3-phenylacetaldehyde by phenylpyruvate decarboxylase (EC 4.1.1.43.) [56] or in
3-phenyllactate by L-lactate dehydrogenase (EC 1.1.1.27.) [46]. Finally, 3-phenylacetaldehyde can be
converted to 3-phenylacetate by phenylacetaldehyde dehydrogenase (EC 1.2.1.39.) [56,57]. All of these
reaction of the phenylalani e metabolic pathway are reversible, which can lead, in the end, to p-cresyl
sulfate generation.
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The degradation routes by the gut microbiota of the aromatic amino acids tyrosine and phenylalanine
are known to a large extent. As shown in Figure 1, several phenolic compounds and intermediates are
generated from tyrosine and phenylalanine through intestinal bacterial fermentation [40–57].
Smith et al. demonstrated that, in the large intestine, bacterial fermentation of proteins mainly
occurs in the distal part of the colon, since they found a four-fold higher concentration of phenolic
compounds in that section of the intestine compared to the proximal bowel. In the distal colon, phenol
and p-cresol account for 70% of all products of the dissimilatory aromatic amino acid metabolism [29].
Accordingly, in batch culture incubations with human faecal slurries, phenol and p-cresol are the
predominant end products of tyrosine fermentation [29,32], whereas the predominant end products of
phenylalanine are phenylacetate and phenylpropionate [29].
3.2. Disturbed Protein Assimilation in CKD
Assimilation of protein (digestion, metabolism, and absorption) in the small intestine is impaired
in both non-dialyzed and dialyzed CKD patients [58,59] which might contribute to protein malnutrition,
a well-known problem in CKD patients [60,61]. The 13C protein breath test is used to measure the
impairment of protein assimilation in CKD, which worsens as kidney function declines. Proteins which
are not absorbed or digested in the small intestine are further metabolized in the colon, by the gut
proteolytic bacteria, which will cause an increase of urinary p-cresol concentration [58,59], an indicator
of colonic p-cresol generation [62,63]. In the small intestine, protein absorption and digestion are also
dependent on the degree of dietary protein intake, which is decreased in many malnourished uremic
patients. This should have a lowering effect on urinary p-cresol [62,64]. However, in the study of
Bammens et al., urinary p-cresol levels were still more pronounced as kidney function declined in CKD
patients, after normalisation for dietary protein intake [58]. Gastro-intestinal motility disorders and
dysbiosis in the gut should also be taken into account when evaluating protein assimilation [58,59].
Conditions that can interfere with protein assimilation are hepatic failure [65], diabetes mellitus [66],
and metabolic acidosis [67]. Whereas hepatic failure and especially diabetes mellitus are frequent
causes of CKD, acidosis is a frequent complication in uremia, accelerating amino acid and protein
catabolism by, e.g., increasing muscle protein breakdown [67,68]. Correction of metabolic acidosis in
CKD patients results in a normalization of the catabolic response to a low-protein diet by reducing
amino acid oxidation and protein degradation, and stimulating protein synthesis to normal levels [68].
4. Gut Microbiota
4.1. Intestinal Phenolic Compounds Generating Microbiota
In general, the most abundant bacterial phyla among the human adult gut microbiota are
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia and, to a lesser extent,
Cyanobacteria, Fusobacteria, Lentisphaerae, Spirochaetes, and TM7 [69]. Obligate anaerobic bacterial
genera such as Bacteroides, Bifidobacterium, and Eubacterium predominantly inhabit the human colon,
while bacterial species of the genera Clostridium, Enterococcus, and Lactobacillus are present to a
lesser extent [70,71]. Macfarlane et al., found in 1986 that proteolytic bacterial species in faeces
are predominantly Bacteroides spp. and Propionibacterium spp. and belong, in a lesser proportion, to
the genera Bacillus, Clostridium, Staphylococcus, and Streptococcus [30]. Gut microbiota are known to
be the source of phenolic compounds, generated in the colon from tyrosine and phenylalanine, as
demonstrated in hemodialysis (HD) patients without colon who have the same plasma pCS levels
as healthy subjects [72]. This was also demonstrated by Wikoff et al., who could not detect pCS
in plasma of germ-free mice [73] and by Kikuchi et al., who observed a non-significant downward
trend in urinary pCS levels in cecectomized rats [74]. Two operational taxonomic units (OTUs),
belonging to the genus Oscillospira and the family Ruminococcaceae, are associated with urinary pCS
levels and one OTU, belonging to the family Ruminococcaceae, is associated with levels of pCG in
healthy subjects [75]. In vitro studies have been carried out to identify the microbiota generating
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phenolic compounds. Table 1 gives an overview of culturable phenolic compound generating
bacteria with predominant phenol-producing bacteria belonging to the Enterococcaceae, Clostridiaceae,
Staphylococcaceae, and Enterobacteriaceae, of which the latter group is known to produce the enzyme
tyrosine phenol-lyase [40,43]. Most studied proteolytic bacteria are of the genus Clostridium [76–79],
of which some can use amino acids as their sole carbon and energy source [76,77]. Additionally,
Bifidobacterium strains are known to ferment aromatic amino acids in the absence of other energy
sources such as carbohydrates [70]. Next to phenol, the main tyrosine end products of several
Clostridium species are p-cresol and 4-hydroxyphenylacetate, the precursor of p-cresol. Additionally,
Bacteroidaceae, Bifidobacteriaceae, Eubacteriaceae, Lachnospiraceae, Porphyromonadaceae, Ruminococcaceae,
and Veillonellaceae have the property to ferment tyrosine to p-cresol and to 4-hydroxyphenylacetate,
while Fusobacteriaceae only generate p-cresol (Table 1). Bone et al. hypothesized that in the large
intestine, phenol-forming bacteria are mainly facultative anaerobes, while p-cresol-forming bacteria
are obligate anaerobes [80]. This hypothesis largely corresponds to the data presented in Table 1.
The kind of phenolic compounds that are generated by gut bacteria can depend on the bacterial strain
under study, but also largely on the carbon and energy source, whereby in vitro study of external
factors, such as medium composition and incubation conditions, can have a large impact on protein
dissimilation [70]. Since only a small fraction of the bacterial gut community is culturable [81], it can
be suspected that the aromatic amino acid fermenting bacteria listed are only the tip of the iceberg. For
future directions, culture conditions will have to be optimized in order to increase the identification
yield of these phenolic compound generating bacteria.
4.2. Gut Dysbiosis in CKD
It has been shown that the composition of the gastro-intestinal microbiota of CKD patients is
altered [82]. More specifically, CKD patients suffer from bacterial overgrowth in the small intestine [83]
with elevated levels of aerobic (106 cells/mL) and anaerobic (107 cells/mL) bacteria in the duodenum and
jejunum [84] and overgrowth of aerobic bacteria in the colon [85,86]. Alterations in the gut microbiota
composition are also observed in nephrectomized rats, who have an increase of Bacteroides species
and a decrease of Lactobacillus species compared with sham-operated rats [87]. Changes in the gut
bacterial species composition may even begin in early stages of CKD, as increased levels of pCS are
associated with an increase of an OTU belonging to the Ruminococcus genus in the early stages of CKD [88].
Vaziri et al. demonstrated that the relative abundance of 190 bacterial OTUs differed between controls
and ESKD patients, whereby ESKD patients had higher amounts of aerobic and facultative anaerobic
bacteria, with the largest increases in the Clostridia, Actinobacteria, and Gammaproteobacteria [82].
To distinguish the effect of uremia, per se, from inter-individual variations, Vaziri et al. investigated the
gut microbial composition in nephrectomized rats. Differences in 175 bacterial OTUs were found with,
more specifically, a decrease in the Lactobacillaceae and Prevotellaceae families in uremic rats. The total
richness was significantly higher in control rats than in the nephrectomized rats [82]. Additionally,
in HD patients, analysis of the faecal microbial composition by culturing techniques revealed an
approximately 100 times higher abundance of aerobes, such as Enterobacteriaceae and Enterococcaceae,
compared to healthy individuals. Of the anaerobes in HD patients, bifidobacteria were decreased while
the number of Clostridium perfringens increased [85]. These findings are consistent with the results of
Fukuuchi et al., studying the faecal microbial composition by traditional plating methods in CKD, HD,
and control patients. However in this study, the total amount of bacteria was decreased in the HD and
CKD groups [86], while Hida et al. found no differences [85]. Among the Enterobacteriaceae, the level of
Escherichia coli was significantly increased in both patient groups compared to the control group [86].
However, when using real-time polymerase chain reaction (PCR) analysis on faecal samples, no
difference was observed in the E. coli level between peritoneal dialysis (PD) patients and controls,
while the Bifidobacterium species decreased [89]. According to Table 1, these studies indicate a higher
prevalence of phenol-producing bacteria belonging to the Enterobacteriaceae and Enterococcaceae families
and of p-cresol-producing bacteria, like C. perfringens in CKD patients. This has been confirmed by the
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quantification of the faecal and serum levels of phenol and p-cresol, which are higher in HD and CKD
patients than in controls [85,86]. The lowered levels of bifidobacteria in CKD, HD and PD [85,86,89]
indicate that these bacterial species are probably not responsible for the increased production of
phenol and p-cresol in these patients, although bifidobacteria have been found to generate phenolic
compounds in in vitro studies (Table 1). From the section above, it becomes clear that the information
in this field of research is still scattered and incomplete, underscoring that the characterization of the
uremic intestinal microbiota will require further investigation before the composition of the responsible
bacterial species, contributing to the increased pCS and phenyl sulfate levels in CKD patients has been
unraveled completely.
Next to the gut microbiota composition, also its functional characteristics play a role in
determining the gut levels of p-cresol. The altered composition of the gastro-intestinal microbiota in
CKD [82] is probably due to bacteria-derived hydrolysis of increased concentrations of urea entering
the intestine via the entero-hepatic cycle, resulting in high levels of ammonia, which elevates the
faecal pH value [90]. Wong et al. demonstrated that 19 microbial families were dominant in ESKD
compared to controls, and that 63% of these dominant microbial families possessed urease-forming
enzymes, needed to convert urea in ammonia. Other dominant families in ESKD (i.e., Clostridiaceae and
Enterobacteriaceae) possess uricase- and p-cresol-forming enzymes, while a lowered family abundance
was found for Lactobacillaceae and Prevotellaceae, producing butyrate-forming enzymes [91] which can
further influence the butyrate production, knowing that this short chain fatty acid has a beneficial
effect on the gastro-intestinal health [69]. Thus, uremia can modify the biochemical milieu of the
gastro-intestinal tract. In addition to uremia itself, therapeutic interventions and dietary restrictions
will also contribute to an altered gut microbiota composition and function [82].
Table 1. Overview of the phenolic compound generating bacterial species (in vitro literature data).
Bacterial Species Tyrosine End Products Phenylalanine End Products




Clostridium bartletti [93] [93] [93] [93]
Clostridium bifermentans [29] [76,92] [29,76]
Clostridium botulinum type G [94] [94]
Clostridium butyricum [80]
Clostridium clostridioforme [70] [70] [70] [70]
Clostridium cochlearium [76]
Clostridium difficile [29,48,76] [29,76] [29,76,92]
Clostridium ghoni [76]
Clostridium lentoputrescens [76] [92]
Clostridium limosum [76]





Clostridium perfringens [29,70] [92] [29]
Clostridium propionicum [76] [76]
Clostridium putrefaciens [76] [76]
Clostridium saccharolyticum [93] [93] [93]
Clostridium septicum [29,80]
Clostridium sordellii [76,92] [76]
Clostridium sporogenes [80] [95] [95]
Clostridium sticklandii [76,94] [76,94]
Clostridium subterminale [76] [76]
Clostridium tetani [76]
Clostridium tetanomorphum [41,76]
Faecalibacterium prausnitzii [93] [93] [93] [93]
Peptostreptococcus anaerobius [95]
Peptostreptococcus asaccharolyticus [29]
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Table 1. Cont.
Bacterial Species Tyrosine End Products Phenylalanine End Products
Phenol p-Cresol 4-Hydroxy-Phenyl-Acetate Phenyl-Acetate Phenyl-Lactate
Enterococcaceae
Enterococcus faecalis [80] a [96]
Enterococcus faecium [97]
Eubacteriaceae
Eubacterium cylindroides [93] [93] [93]
Eubacterium hallii [93] [93]





Lactobacillus casei [46] [46] [76]
Lactobacillus casei Shirota [70]
Lactobacillus confusus [97] b
Lactobacillus coryniformis [99]
Lactobacillus fermentum [97]








Anaerostipes caccae [93] [93] [93]
Anaerostipes hadrus [93] [93] [93]
Butyrivibrio fibrisolvens [93] [93] [93]
Roseburia intestinalis [93] [93] [93] [93]
Roseburia inulinovorans [93] [93] [93]
Ruminococcaceae
Ruminococcus obeum [93] [93] [93] [93]
Ruminococcus sp. [93] [93] [93]
Ruminooccus torques [93] [93] [93]
Staphylococcaceae
Staphylococcus epidermidis [80] c [80] c
Veillonellaceae




Bacteroides eggerthii [93] [93]
Bacteroides fragilis [29] [29,80,93] [92,93] [29,70,92,93]
Bacteroides gingivalis [92]
Bacteroides ovatus [29,93] [29,92,93] [29]
Bacteroidesruminicola subsp. brevis [92]
subsp. Ruminicola [92]
Bacteroides thetaiotaomicron [29,70] [70,93] [29,70,92,93]
Bacteroides uniformis [93] [93] [93]
Bacteroides vulgatus [93] [93]
Porphyromonadaceae
Parabacteroides distasonis [93] [93] [93]
ACTINOBACTERIA
Bifidobacteriaceae
Bifidobacterium adolescentis [29,93] [29,93] [93]
Bifidobacteriumanimalis subsp. Lactis [70] [70]
Bifidobacterium bifidum [29] [29]
Bifidobacterium infantis [29,93] [29,93] [93] [93]
Bifidobacterium longum [29] [29] [29,70]
Bifidobacterium pseudolongum [29] [29]
Bifidobacterium sp. [80]
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Table 1. Cont.
Bacterial Species Tyrosine End Products Phenylalanine End Products
Phenol p-Cresol 4-Hydroxy-Phenyl-Acetate Phenyl-Acetate Phenyl-Lactate
PROTEOBACTERIA
Enterobacteriaceae
Citrobacter freundii [40] d, [42]
Citrobacter intermedius [40] e
Enterobacter aerogenes [40] f
Escherichia coli [29,40,80]





a mentioned in original paper as Streptococcus faecalis; b mentioned in original paper as Weisella confusa; c mentioned
in original paper as Staphylococcus albus; d mentioned in original paper as Escherichia freundii; e mentioned in original




Literature reports on biological activity of pCS only emerged during the last decade, as until
2005, due to a preparative artefact caused by using acidification for deproteinization of plasma,
its intestinally-generated precursor, p-cresol, was thought to be retained in the circulation [39].
Shortly after de Loor et al. [36] and Martinez et al. [103] reported this phenomenon independently
from each other by using alternative deproteinization protocols (acetone and methanol, respectively),
a first in vitro study by Schepers et al. pointed to a role of pCS in causing increased oxidative stress
in leukocytes [104]. In vivo intravital microscopy in rat peritoneal capillary venules confirmed the
stimulatory effect of pCS on leukocytes showing an increase in the number of rolling leukocytes along
the vascular endothelium after superfusion of the peritoneal membrane with a solution containing
pCS at uremic concentration [105]. Furthermore, pCS stimulated endothelial microparticle release,
a marker of endothelial damage [106], and induced oxidative stress in both human umbilical vein
endothelial cells (HUVECs) and human vascular smooth muscle cells (HVSMCs) [107]. Ex vivo, pCS
induced contraction of mouse thoracic aorta, through direct activation of rho-kinase, independently of
oxidative stress induction, as well as inward eutrophic vascular remodelling [107]. Furthermore, pCS
induced NADPH oxidase activity and reactive oxygen species (ROS) production in cardiomyocytes
facilitating cardiac apoptosis and resulting in diastolic dysfunction in nephrectomized mice [108].
These data suggest that pCS might contribute to cardiovascular morbidity and mortality in CKD.
In addition, toxic effects on renal tubular cells have also been reported. pCS increased expression
of DNA methyltransferases 1, 3a, and 3b isoforms which suppressed Klotho expression in HK2 cells
and injection of pCS in uninephrectomized B-6 mice caused kidney fibrosis, CpG hypermethylation
of the klotho gene, and decreased klotho expression in the renal tubular cells [109]. Sun et al. also
demonstrated that pCS activated the renal renin angiotensin aldosterone system/transforming growth
factor-beta pathway and induced epithelial-to-mesenchymal transition-like transition contributing
to kidney injury and fibrosis [110]. In parallel to what is observed at the cardiovascular level, pCS
also induces NADPH oxidase driven production of ROS next to expression of inflammatory cytokines
in renal tubular cells, a process involved in kidney fibrosis [111]. This pro-inflammatory, but also
pro-apoptotic, effect of pCS on human proximal tubular epithelial cells (PTEC) was confirmed by
Poveda et al. [112]. Interestingly, pCS was shown to inhibit the activity of the human conditionally
immortalized PTEC efflux transporters Multidrug Resistance Protein 4 (MRP4) and Breast Cancer
Resistance Protein (BCRP), by 40% and 25%, respectively. These are two efflux transporters involved
in pumping solutes out of the tubular cell, of which inhibition may possibly lead to intracellular
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accumulation and increased toxicity of the substrates of those transporters which are various organic
acids amongst which pCS, which may contribute to progression of CKD [113].
Finally, pCS was shown to play a role in insulin resistance, in aberrant adipose tissue metabolism,
and reallocation of fat in the body [114], in hampering calcium deposition and osteoprotegrin expression
in human mesenchymal stem cells and in suppressing the immune response by Th1-cells [115] and
macrophages [116].
Hence, pCS contributes to many mechanisms that are involved in cardiovascular and renal
damage. The question is whether these experimental findings are corroborated in clinical studies.
5.2. Clinical Associations
As summarized in Table 2, both increasing levels of total and free pCS [117–128], as well as
its urinary excretion [129], have been repeatedly associated with cardiovascular complications and
mortality in patients with CKD whether or not on dialysis [130]. In addition, total pCS has been linked
to progression of renal failure [131]. Recently, total pCS also has been associated with pruritus in
CKD [132].
Table 2. Studies describing associations between p-cresyl sulfate concentrations and clinical parameters
and outcomes of patients with chronic kidney disease.
Patient Type Patient Number Total or Free pCSConcentration Association Ref.
Diabetic nephropathy 209 total CAD [118]
Stable angina 202 total Severity of CAD [126]
Stable angina with early CKD 154 total QTc prolongation [125]
CKD and stable angina 403 total LV systolic function [122]
CKD 72 total CV and dialysis event (progression) [121]
149 free and total free IL-6 and PWV Plasma glutathione peroxidase [123]
200 urinary excretion CV event [129]
268 total Renal progression and all-cause mortality [131]
320 total Pruritus [132]
CKD and CAD 340 total MACE [127]
CKD and HD (32%) 139 free Survival [133]
HD 91 free Survival and function of vascular access [117]
100 total Ankle Brachial index, AV-shunt failure andvascular access failure event [120]
209 total Co-morbidity of CAD and DM * [119]
394 total CV mortality and first CV event [124]
Elderly HD 112 free All-cause and CV mortality [128]
AV: arterio-venous; CAD: coronary artery disease; CKD: chronic kidney disease; CV: cardiovascular; DM: diabetes
mellitus; HD: hemodialysis; IL-6: interleukin-6; LV: left ventricle; MACE: major cardiovascular events; pCS: p-cresyl
sulfate; PWV: pulse wave velocity; QTc: heart-rate corrected QT interval; * not with pro-inflammatory markers.
6. Therapeutic Methods for Reducing p-Cresyl Sulfate Concentration
6.1. Affecting the Generation of pCS
Most strategies to lower plasma pCS levels (summarized in Table 3) are based on solute removal
by dialysis (see below) and are, to a lesser extent, focused on suppressing solute production.
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6.1.1. Diet
Diet has a major effect on the gut microbial composition, considering that healthy colon microbiota
is primarily composed by s ccharolytic bacteria whereas, in CKD, pr teolytic bacteria predominate.
Saccharolytic bacterial species mainly ferment carbohydrates, which yields short chain fatty acids, such as
acetate, butyrat , and propion te, which are beneficial to the host [17]. Proteolytic bacterial species, on the
other hand, predominantly metabolize proteins resulting in the generation of a variety of end products
including short or branched chain fatty acids, ammonia, amines, thiols, phenols, and indoles, some of
which h ve toxic properties [134]. Thus, potential way to lower the eneration of proteolysis-derived
microbial metabolites such as phenol and p-cresol is trying to alter the gut metabolism in favour of
a saccharolytic profile by increasing the dietary intake of co plex carbohydrates and fibers while
decreasing dietary protein intake [29,134], a d some data i deed suggest that this is the case [17,135].
Exclusion of dietary protein intake by adhering to a vegan diet was shown to decrease bacterial urease
activity by 66% [136], an also to ca s a decline f serum and urinary p-cr sol and phenol levels [136].
Patel et al. demonstrated a decrease of urinary pCS levels by 62% in healthy vegetarians, who consume
25% less protein and 69% more fibre than individuals consuming an unrestricted diet [137]. To the
contrary, when tein intake w s e r ched by 8.4% in healthy humans, urinary p-cresol levels increased
from a mean concentration of 7.71 ± 2.47 mg/g creatinine in the control period to 17.59 ± 4.58 mg/g
creatinine in the protein rich period [64]. This is in agreement with a study in healthy subjects on
a control e diet, whereby increasing e protein intake by 73.3 g/day, mainly by increasing meat
intake, resulted in a an elevation of the level of total urinary volatile phenol from a concentration
of 74 ± 14.5 mg/day in the low protein di t period to 108 ± 14.6 mg/day in the high protein diet
period. On other hand, addition of 29.8 g of wheat fibre per day to the high protein diet induced a
non-significant downward trend in total urinary phenol levels [138]. However, for some bacterial
sp cies the presenc of ca bohydrates also stimulat the dissimilation of aromatic amino acids [29] or
is needed for activating the aromatic amino acid metabolism because of their inability to use amino
acids as their sole carbon and energy source [93]. Birkett et al. demonstrated in healthy volunteers that
a diet consisting of high re ist nt starch decreased f ecal p-cr ol and phe ol concentrations by about
29 ± 2 µg/g and 1.0 ± 0.1 µg/g, respectively, however without a significant effect on urinary p-cresol
concentrations [139]. Rossi et al. showed that carbohydrates are an important factor in reducing free
and total pCS levels in non-dialyzed CKD patients, with total dietary fibre, negatively, and protein-fibre
index, positively associated with total serum pCS [140]. Additionally, in HD patients, increased dietary
fibre i take resulted in a low r free plasma pCS [141]. An anim l st dy in uremic rats ingesting
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fermentable dietary fibre high amylose maize resistant starch type 2 (HAMRS2) resulted in a decrease
of cecal pH and urinary p-cresol by 47%. The microbial diversity was also decreased in this group
while the Bacteroidetes-to-Firmicutes ratio increased. The latter is considered to be an indicator of a
healthy gut [142]. It is of note a rigid dietary protein restriction in CKD/HD patients is not a good
solution to diminish uremic toxins level because inadequate dietary protein intake contributes to
malnutrition [58]. According to the British diabetic association evidence-based guidelines, a minimum
protein intake of 1.1 g/kg ideal body weight (IBW)/day and 1.0–1.2 g/kg IBW/day is required for HD
and PD patients, respectively [143]. Irrespective of protein intake, patients with CKD are in addition
often prescribed a combined diet to prevent fluid overload, hyperphosphatemia and hyperkalemia,
with restrictive intake of fruits, vegetables, and high-fibre products [82], which is likely to alter the
fermentation in favour of a proteolytic profile, increasing the generation of the unwanted phenolic
compounds. In a meta-analysis, supplementation of a restricted protein diet with ketoacid analogues of
essential amino acids has been suggested to delay the progression of CKD effectively without causing
malnutrition [144]. In addition, this therapy has been shown to improve the native arteriovenous
fistula maturation, to decrease the initial vascular stiffness and to limit inflammatory response in
CKD patients [145]. However, the effects of keto-analogues on intestinal microbiota and on levels of
intestinally-generated uremic toxins has to our knowledge as yet not been evaluated.
6.1.2. Probiotics, Prebiotics, and Synbiotics
Several studies demonstrated favourable effects on p-cresol metabolism due to the administration
of probiotics, prebiotics, and synbiotics [85,146–157]. In general, pre- and probiotics aim to increase the
saccharolytic activity of colonic bacteria because of the beneficial effects attributed to the end products
of carbohydrate fermentation and to decrease the generation of the proteolytic fermentation end
products of which some have toxic effects [146]. Administration of the probiotic Lactobacillus acidophilus
(1 × 1010 CFU/kg/day) mitigated urinary protein excretion in nephrectomised rats and lowered
serum pCS levels. However, administration of L. acidophilus had no effect on faecal p-cresol and phenol
levels. This suggests that the reduced serum pCS levels are primarly due to blocking of p-cresol
entry from the intestine into the circulation through restoring the intestinal tight junction protein
expression by L. acidophilus [87]. With regard to the effect of probiotics on the pCS levels in healthy
humans, as reviewed by Rossi et al. [147], it has been shown that probiotic Lactobacillus strains are
associated with a decreased urinary p-cresol excretion [148] along with decreased faecal bacterial
β-glucuronidase, nitroreductase and glycocholic acid hydrolase enzyme activities [158]. At least
one strain of Lactobacillus gasseri has the ability to decrease faecal p-cresol levels in healthy subjects
and to lower the number of cells of Staphylococcus [149], a proteolytic bacterium [30]. Also dietary
addition of the probiotic Lactobacillus casei Shirota strain or the probiotic Bifidobacterium breve Yakult
strain resulted in a decrease of urinary p-cresol in healthy volunteers [146]. Furthermore, Lebenin,
an oral preparation of lactic acid bacteria containing Bifidobacterium infantis, Enterococcus faecalis,
and L. acidophilus decreased faecal p-cresol levels in healthy persons [85]. In contrast, in pediatric
HD and PD patients, a high concentration of a probiotic preparation, containing Lactobacillus spp.,
Bifidobacterium spp., and Streptococcus salivarius subsp. thermophilus, had no effect on the serum pCS
levels [159]. Lowering the pH value by lactic acid producing bacteria, such as Lactobacillus and
Streptococcus spp., reduced the dissimilatory metabolism of aromatic amino acids [29] and suppressed
aerobic bacterial overgrowth [85], which in its turn reduces the accumulation of pCS.
Administration of prebiotics, such as lactulose or oligofructose-enriched inulin (OF-IN) to
healthy humans, resulted in a significant reduction of p-cresol in the urine for both substrates, with
OF-IN having the largest effect (from 27.7 ± 15.3 mg/day to 17.8 ± 10.8 mg/day) compared to
the lactulose group (from 20.7 ± 11.6 mg/day to 12.7 ± 8.9 mg/day) [150]. Using real-time PCR,
it was shown that the total number of bifidobacteria in faeces were elevated after administration
of both prebiotics [146,150]. Davis et al. demonstrated that administration of the prebiotic
galacto-oligosaccharide (GOS) during 12 weeks to healthy humans resulted in a dose-dependent
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increased abundance of actinobacteria with specific enrichment of bifidobacteria at the expense of the
Bacteroides group [151]. In HD patients, OF-IN decreased the pCS generation rate and serum pCS
concentrations by 20% [152]. Acarbose, a small intestinal α-glucosidase inhibitor, is another prebiotic
that is administered to increase undigested carbohydrate levels in the colon. Acarbose was shown
to lower serum p-cresol concentration and urinary p-cresol excretion, the latter reflecting its colonic
generation rate [153]. However, Poesen et al. could not establish any effect of the prebiotic arabinoxylan
oligosaccharide on serum and 24 h urinary excretion pCS and pCG levels in CKD patients [154].
Finally, the combination of pre- and probiotics, the so-called synbiotics, more recently gained
interest. In healthy humans, long-term administration of the L. casei Shirota strain in association
with OF-IN resulted in a significant urinary p-cresol reduction [146]. Similar effects were shown in
HD patients, in who synbiotic administration, consisting of the L. casei Shirota strain, the B. breve Yakult
strain, and GOS, decreased serum p-cresol levels [155]. Additionally, Probinul-neutro, a synbiotic
containing Lactobacillaceae, Bifidobactericeae, S. thermophilus, inulin, and tapioca-resistant starch, reduced
total plasma p-cresol concentrations in non-dialyzed CKD patient stages 3–4 [156]. In a randomized
controlled trial (RCT), Rossi et al. recently demonstrated a significant reduction of serum pCS in CKD
patients administered a combination of inulin, fructo-oligosaccharides, GOS, and different strains
belonging to the genera Lactobacillus, Bifidobacteria, and Streptococcus. This decrease was even more
marked if the patients who had received antibiotics in this study (about 1/3 of the enrolled subjects)
were excluded [157].
6.1.3. Laxatives
In CKD patients, the colonic transit time is prolonged mainly in the colon ascendens and in the
recto-sigmoid segment [160]. Constipation was documented to occur more frequently in HD patients
(63.1% of 268 patients) compared to continuous ambulatory peritoneal dialysis (CAPD) patients
(28.9% of 204 patients) [161]. The higher frequency of constipation, in general, is due to several factors,
such as dietary restrictions, medication, lifestyle, low fluid intake, and comorbidity [8]. Longer colonic
transit time results in an elevated bacterial fermentation of amino acids [75,138] and may subsequently
induce an overgrowth of proteolytic bacteria in the human colon. In a study of Roager et al., urinary
pCS and pCG correlated positively with colonic transit time [75]. A consecutive stepwise three-stage
in vitro culture model mimicking the colon with fresh faecal slurries as initial substrate entered into
the system showed a higher p-cresol and phenol concentration with longer transit time [29]. From this




Decreasing the uptake of colon-derived solutes by administering oral adsorbents, such as AST-120,
might be another option to lower pCS levels. Administration of AST-120 in CKD rats resulted in a
decrease of serum pCS [162] and of p-cresol levels and a reduction of p-cresol urinary excretion [163].
This is in agreement with a recent study of Velenosi et al., demonstrating a significant reduction of pCS
and pCG in plasma, heart, kidney, and liver of uremic rats after AST-120 administration [164]. Next to
decreasing serum and urinary pCS levels, AST-120 also changed overall gut microbiota composition in
uremic rats [74]. In dialyzed patients, treatment with AST-120 resulted in a decrease of total and free
pCS plasma levels [165,166]. Thus, AST-120 is a potential treatment to lower pCS and even pCG levels
in CKD patients, but this treatment does not have a lasting effect after intake discontinuation [165].
Two recent RCTs in CKD patients, in which plasma levels of pCS were not reported, showed no
beneficial effect of AST-120 on the progression of CKD [167,168]. In one of these studies, however,
the evolution of the concentration of another protein-bound compound, indoxyl sulfate (IxS), was
followed, without changing a change in concentration in the group on AST-120 [168].
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6.3. Preserving Kidney Function
In healthy kidneys, urinary excretion of protein-bound metabolites like pCS is, in large part,
determined by tubular secretion rather than filtration, which shifts the binding and allows active
secretion of these solutes. To mediate urinary solute excretion, renal proximal tubules are equipped
with a range of transporters that cooperate in basolateral uptake (e.g., organic anion transporter
(OAT)-1 and OAT-3) and luminal excretion, such as multidrug resistance protein (MRP)-4 and breast
cancer resistance protein (BCRP). It is conceivable that these functions are lost as kidney failure
progresses and that any intervention to prevent this progression will also result in less retention of
uremic solutes, including pCS.
6.4. Dialysis and Renal Transplantation
6.4.1. Dialysis
Due to their binding, protein-bound uremic toxins, such as pCS, are poorly filtered across
dialysis membranes. Pre-and post-dilution hemodiafiltration (HDF) increased the reduction ratios
of pCS when compared to high flux hemodialysis (HFHD) [169] and when compared to pre-dilution
hemofiltration [170]. Thus, combining convective with diffusive removal seems to improve removal
of protein-bound toxins during dialysis. However, these results were not confirmed in a study
by Krieter et al. [171], who did not find superior reduction ratios for pCS with post-dilution HDF
compared to HFHD. In a longitudinal setting, after six months of treatment with pre-dilution
hemofiltration, the concentrations of total and free p-cresol, representing the combination of pCS
and pCG, were reduced compared to low-flux dialysis used before the start of the study [10]. Similarly,
a decrease in the predialysis concentration of total pCS was observed after nine weeks of post-dilution
HDF compared to high-flux dialysis before the start of the study [172]. Even if reductions with
convective strategies are significant, the question is whether these changes are clinically relevant.
Increase in dialysate flow (QD) and dialyzer surface (KoA) is another way to increase the clearance of
pCS [173]. The same group pointed to the fact that in dialysis patients, a notable fraction of the weekly
solute removal of protein-bound toxins is accomplished by residual renal function (RRF) [174].
A possible promising strategy to optimize the removal of protein-bound toxins could be the
use of sorbent technology in dialysis. Using fractional plasma separation and absorption (FPAD),
the reduction ratios of p-cresol were doubled in comparison to HFHD. This study however, was
discontinued due to serious clotting problems [175]. In a more recent study, removal rates of FPAD
treatment in comparison to HFHD were 127% for p-cresol [176]. In an in vitro setting, pCS was fully
absorbed from dialysate by a commercially available activated carbon sorber [177]. In pilot in vitro
experiments, mixed matrix membranes, that contained incorporated activated carbon, adsorbed on
average 2.27 mg pCS/g membrane in 4 h in diffusion experiments and 2.68 mg pCS/g membrane
in convection experiments. It was estimated that the membranes would suffice to remove the daily
production of pCS [178]. Recently, alternative sorbents were proposed. A nanoporous activated carbon
monolith prototype designed for direct blood contact was shown to almost completely remove pCS
in vitro [179] and highly porous microparticles prepared from poly(etherimide) were also able to
highly absorb pCS with high affinity [180]. In an in vitro hemodiafiltration setting aiming to interfere
with protein binding by increasing plasma ion strength (IPIS; hypertonic NaCl solution), the clearance
of pCS was increased by 53.6% ± 10.2% [181]. In a pilot RCT comparing HDF-IPIS to HD and HDF
only an increase in dialytic clearance of free IxS, but not of pCS was observed [182].
In PD, the total clearance, dialysis plus RRF, of p-cresol as surrogate for pCS was markedly
lower compared to HFHD, in spite of less removal per unit of time with PD [183]. In contrast to the
water-soluble compounds, PD clearance of pCS did not increase when RRF was lost, but nevertheless
no rise in their plasma concentration occurred [184]. In a more recent prospective observational cohort
of incident PD patients, PD clearance tended to increase, but did not compensate for the declining
renal clearance, with as a consequence that serum pCS concentrations increased in parallel with
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loss of RRF [185]. The importance of RRF in removal of pCS in PD patients was recently confirmed
by Huang et al. [186]. The fact that, despite the lower removal rate, the plasma concentration of
protein-bound compounds is lower in PD patients that in HD patients [183,184], is suggesting that other,
possibly metabolic, factors are determining pCS concentrations [187]. Additionally, in HD patients,
concentrations of pCS seem dependent on protein equivalent of nitrogen appearance and not on
dialysis adequacy as assessed by Kt/V (urea) [188].
6.4.2. Renal Transplantation
Finally, with renal transplantation, decreases of serum pCS (and pCG) were observed at each
of the analysed time points post-transplantation (day 7 and three and 12 months) [189]. Levels were
significantly lower in transplant recipients when compared with CKD control patients with the same
kidney function. Further analysis demonstrated significantly lower 24 h urinary excretion of these
solutes in transplant recipients in spite of virtually identical glomerular filtration rates (GFR) [190].
Thus, differences in GFR do not seem to play a major role in this lower concentration of pCS among
renal transplants. These changes may be due to immunosuppressive agents, antibiotics, other drugs,
the transplantation procedure itself [191].
7. Conclusions and Future Perspectives
The protein-bound uremic toxin, p-cresyl sulfate, originates from the bacterial metabolism in the
intestine and several phenolic compound-generating bacteria have been identified. Circulating levels
of pCS are increased in CKD and increased levels have been associated with worse outcome of CKD
patients. The currently available therapeutic methods trying to decrease levels of pCS, among other
protein-bound uremic toxins, still remain inadequate. Targeting its generation seems an attractive
measure, which could not only be applied as a preventive measure at earlier stages of CKD, but
also in addition to dialysis at the end stage. Development of intervention strategies at the level of
the intestinal microbiota first needs a thorough characterization of the uremic microbiome and its
functional capacity.
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